These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

492 related items for PubMed ID: 16618399

  • 1. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial.
    Lémann M, Mary JY, Duclos B, Veyrac M, Dupas JL, Delchier JC, Laharie D, Moreau J, Cadiot G, Picon L, Bourreille A, Sobahni I, Colombel JF, Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID).
    Gastroenterology; 2006 Apr; 130(4):1054-61. PubMed ID: 16618399
    [Abstract] [Full Text] [Related]

  • 2. A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab.
    Mantzaris GJ, Viazis N, Petraki K, Papamichael K, Theodoropoulos I, Roussos A, Karakoidas C, Koilakou S, Raptis N, Smyrnidis A, Agalos G, Karamanolis DG.
    Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1042-8. PubMed ID: 20139856
    [Abstract] [Full Text] [Related]

  • 3. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S.
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [Abstract] [Full Text] [Related]

  • 4. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease.
    Ochsenkühn T, Göke B, Sackmann M.
    Am J Gastroenterol; 2002 Aug; 97(8):2022-5. PubMed ID: 12190171
    [Abstract] [Full Text] [Related]

  • 5. Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease.
    Navarro FA, Hanauer SB, Kirschner BS.
    J Pediatr Gastroenterol Nutr; 2007 Sep; 45(3):312-8. PubMed ID: 17873743
    [Abstract] [Full Text] [Related]

  • 6. A review of infliximab use in ulcerative colitis.
    Wilhelm SM, McKenney KA, Rivait KN, Kale-Pradhan PB.
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [Abstract] [Full Text] [Related]

  • 7. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease.
    Reinisch W, Panés J, Lémann M, Schreiber S, Feagan B, Schmidt S, Sturniolo GC, Mikhailova T, Alexeeva O, Sanna L, Haas T, Korom S, Mayer H.
    Am J Gastroenterol; 2008 Sep; 103(9):2284-92. PubMed ID: 18671816
    [Abstract] [Full Text] [Related]

  • 8. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M.
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [Abstract] [Full Text] [Related]

  • 9. Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study.
    Chebli JM, Gaburri PD, De Souza AF, Pinto AL, Chebli LA, Felga GE, Forn CG, Pimentel CF.
    J Gastroenterol Hepatol; 2007 Feb; 22(2):268-74. PubMed ID: 17295882
    [Abstract] [Full Text] [Related]

  • 10. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R, REACH Study Group.
    Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [Abstract] [Full Text] [Related]

  • 11. Clinical experience with infliximab therapy in 100 patients with Crohn's disease.
    Farrell RJ, Shah SA, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P, Peppercorn MA.
    Am J Gastroenterol; 2000 Dec; 95(12):3490-7. PubMed ID: 11151882
    [Abstract] [Full Text] [Related]

  • 12. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
    Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, Patel K, Wolf DC, Safdi M, Colombel JF, Lashner B, Hanauer SB.
    Gastrointest Endosc; 2006 Mar; 63(3):433-42; quiz 464. PubMed ID: 16500392
    [Abstract] [Full Text] [Related]

  • 13. Infliximab in Crohn's disease: first anniversary clinical experience.
    Cohen RD, Tsang JF, Hanauer SB.
    Am J Gastroenterol; 2000 Dec; 95(12):3469-77. PubMed ID: 11151879
    [Abstract] [Full Text] [Related]

  • 14. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.
    Kinney T, Rawlins M, Kozarek R, France R, Patterson D.
    Am J Gastroenterol; 2003 Mar; 98(3):608-12. PubMed ID: 12650795
    [Abstract] [Full Text] [Related]

  • 15. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q, Hogezand RA, Lamers CB, Verspaget HW.
    Aliment Pharmacol Ther; 2004 Sep 01; 20(5):585-92. PubMed ID: 15339330
    [Abstract] [Full Text] [Related]

  • 16. Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: a double-blind placebo-controlled study.
    Omer B, Krebs S, Omer H, Noor TO.
    Phytomedicine; 2007 Feb 01; 14(2-3):87-95. PubMed ID: 17240130
    [Abstract] [Full Text] [Related]

  • 17. Infliximab in the treatment of steroid-dependent ulcerative colitis.
    Armuzzi A, De Pascalis B, Lupascu A, Fedeli P, Leo D, Mentella MC, Vincenti F, Melina D, Gasbarrini G, Pola P, Gasbarrini A.
    Eur Rev Med Pharmacol Sci; 2004 Feb 01; 8(5):231-3. PubMed ID: 15638236
    [Abstract] [Full Text] [Related]

  • 18. Steroid-independent Crohn's disease patients also benefit from combination therapy of infliximab plus azathioprine.
    van den Brande JM, Peppelenbosch MP, Hommes DW.
    Gastroenterology; 2006 Oct 01; 131(4):1362-3. PubMed ID: 17030216
    [No Abstract] [Full Text] [Related]

  • 19. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.
    Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, Stokkers P, Hommes D, Rutgeerts P, Vermeire S, D'Haens G, Belgian Inflammatory Bowel Disease Research Group, North-Holland Gut Club.
    Gastroenterology; 2010 Feb 01; 138(2):463-8; quiz e10-1. PubMed ID: 19818785
    [Abstract] [Full Text] [Related]

  • 20. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.
    Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P.
    Gastroenterology; 2003 Apr 01; 124(4):917-24. PubMed ID: 12671888
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.